Pancreatic adenocarcinoma is the fourth leading cause of death from malignant diseases (Poston et al., 1991) . The aggressive nature of the neoplasia, the lack of early detection, and the limited response to the treatment including chemotherapy and radiotherapy contribute to the high mortality rate from the disease. Therefore, a better understanding of the molecular mechanisms leading to this tumor remains a major goal because it may help in devising strategies for earlier diagnosis and better treatment. It has been shown that most human pancreatic cancers harbor mutations in the K-ras oncogene (Almoguera et al., 1988; Smit et al., 1988) and these may represent a relatively early event in pancreatic tumorigenesis (Lemoine et al., 1992) . The oncogenic mutation of the K-ras gene stabilizes the Ras protein in a GTP-bound form, which is constitutively active. The expression of active Ras mutants in established cell lines can lead to cellular transformation, which is inhibited by dominant negative mutant of H-ras (N17) (Feig and Cooper, 1988) .
Ras has been shown to mediate activation of various downstream targets. One of these downstream targets is the family of the mitogen-activated protein kinase (MAPKs). There are three well-defined MAPK pathways: extracellular signal-regulated kinases (ERKs), cJun N-terminal kinases (JNKs) and the p38 MAPKs. It has been demonstrated that ERK is involved in cell proliferation and transformation (Pages et al., 1993; Brunet et al., 1994; Ferrell, 1996; Troppmair et al., 1994) . JNK activation has been implicated in various, often opposing cellular responses, such as cell proliferation, transformation (Antonyak et al., 1998; Bost et al., 1997; Clark et al., 1997; Minden et al., 1994; Smeal et al., 1991 Smeal et al., , 1992 , and apoptosis (Leppa and Bohmann, 1999; Karin et al., 1997) . Activation of the MAPK cascade has been shown to be essential to activation of transcriptional factor AP-1 (activator protein 1). AP-1 plays an important role in cell proliferation, differentiation, apoptosis and transformation (Watts et al., 1998; Xiao and Lang, 2000; Leppa and Bohmann, 1999; Karin et al., 1997) . It is composed of homo-and heterodimeric complexes of Jun, Fos and ATF family members and regulates transcription by interacting with the AP-1 sites TGACTCA (Angel et al., 1987) and the cAMP response element (CRE), TGACGTCA (Benbrook and Jones, 1990) .
Although ERK is involved in cell proliferation and transformation, it has been reported that the MEK -ERK cascade is not always constitutively activated in pancreatic cancer tissues (Yip Schneider et al., 1999) and cell lines (Hoshino et al., 1999; Giehl et al., 2000) harboring oncogenic K-ras. In pancreatic cancer cells, it remains to be elucidated whether the MAPK pathway is activated or not and what downstream transcriptional factors are involved in abnormal proliferation or other process.
First, to investigate whether the ERK and JNK are activated in pancreatic cancer tissues, Western blot analyses using antibodies that specifically recognize phosphorylated form of ERK or JNK were performed on clinical samples of cancer tissues and adjacent normal tissues from the same patient obtained by needle biopsy (Figure 1 ). In three of the nine cases, samples obtained from tumor showed stronger bands of phosphorylated and activated ERK than those from the adjacent normal tissues ( Figure 1a ). As shown in Table 1 , no apparent correlation was observed between ERK activation in tumors and age, gender, size of tumor, or metastases, however ERK activation was observed more often in pathologically poorly differentiated samples. JNK activation (Figure 1b) was observed in all the pancreatic cancer tissues in the nine cases examined (Table 1) .
To examine the specific role of JNK activation in pancreatic cancer cells, colony formation assays were performed in four anchorage-independent and tumorigenic pancreatic adenocarcinoma cell lines using dominant negative mutants of various members of MAP kinase cascades in Ras -MEKK -JNK pathway: three cell lines with mutated K-ras (PANC-1, MIAPaCa-2 and AsPC-1 cells) and one with wild K-ras (BxPC-3), and in two cell lines as controls, an amnionderived immortalized cell line, FL, and a hepatocellular carcinoma cell line, HuH-7. Cells were transfected with expression plasmids for the dominant negative forms of Ras (DN -Ras), MEKK1 (DN -MEKK), ERK1 (DN -ERK1), and ERK2 (DN -ERK2), in addition to a G418 selectable marker, pRC/RSV. For colony formation assays, the transfected cells were plated and selected with G418, and then the numbers of the survived colonies were counted to evaluate the effects of the dominant-negatives on the efficacy of G418-resistant colony formation. As shown in Figure 2 , induction with DN -Ras decreased the number of colonies in all pancreatic cancer cell lines except the PANC-1 cells. Inhibition of the ERK pathway by expression of DN -ERK1 or DN -ERK2 resulted in moderate decrease in colony formations. When DN -MEKK was transfected, the number of colonies was substantially decreased in all pancreatic cancer cell lines, especially in the BxPC-3 and PANC-1 cells, but in the FL and HuH-7 cells DN -MEKK did not remarkably reduce the number of surviving colonies when compared to the pancreatic cancer cells. These results indicated that DN -MEKK suppresses the survival of the pancreatic cancer cells but not of the non-pancreatic cancer cells. The colony sizes were not affected by the DN -MEKK (Table 2) in FL cells and pancreatic cancer cells, suggesting that the DN -MEKK inhibits the cell survival rather than the cell proliferation.
Among the dominant negative mutants the DN -MEKK strongly inhibited colony formation in all pancreatic cancer cell lines. These results prompted us to further investigate the mechanisms of the inhibitory effects of DN -MEKK expression on the colony survival of pancreatic cancer cell lines. To examine the effect of DN -MEKK on JNK activity, in vitro kinase assays using GSTc-Jun as a substrate were employed, and revealed that DN -MEKK inhibits JNK activity in FL cells, but not in pancreatic cancer cells (Figure 3a) . Luciferase assays showed that DN -MEKK suppresses the JNK-mediated activity of Gal4c-Jun in FL cells, but not in pancreatic cancer cells (Figure 3b ). These results suggest that DN -MEKK does not inhibit JNK activity in pancreatic cancer cells.
Since the Ras -MEKK -JNK pathway regulates members of AP-1/ATF transcriptional factors, which Figure 1 Western blot analysis of the ERK and JNK in pancreatic cancer tissues and adjacent normal pancreas tissues. Tissue samples obtained from tumour (T) and adjacent normal pancreas (N) by needle-biopsy were separated on 12% SDS -PAGE and transferred to PVDF membranes. Western blots were first incubated with antibodies specific for the phosphorylated ERK, phosphorylated-independent ERK (a), phosphorylated JNK and phosphorylated-independent JNK (b) (Santa Cruz Biotech), and then with horseradish peroxidase-conjugated secondary antibodies. Immunocomplexes were detected by the ECL Western blotting analysis system (Amersham Pharmacia Biotech) bind to AP-1 site/CRE, the effect of DN -MEKK expression on the DNA-binding activities of these transcriptional factors were examined. To address the observed differences in the effect of FL and pancreatic cancer cells on colony survival, electrophoretic mobility shift assays (EMSAs) were performed with radiolabeled oligonucleotides, which contained the consensus AP-1 site or CRE. Transfection of the DN -MEKK into pancreatic cancer cells reduced the DNA-binding 
Plasmids expressing dominant negatives of ras (DN -ras), MEKK1 (DN -MEKK), ERK1 (DN -ERK1), ERK2 (DN -ERK2
) or a control empty vector were cotransfected into cells with pRC/RSV as a G418 selectable marker by using electroporation. Twenty-four hours after the transfection, G418 (GIBCO -BRL) was added at a concentration of 400 mg/ ml 71 for BxPC-3 and HuH-7 cells, 800 mg/ml for MIAPaCa-2 and FL cells and 1200 mg/ml for AsPC-1 and PANC-1 cells. The numbers of G418-resistant colonies stained with Giemsa were counted on the 14th day. The bars indicate the percentages of the number of G418-resistant colonies relative to the control vector. Error bars indicate the standard errors of at least four independent experiments (Figure 4a ). Similar results were obtained with the CRE probe in PANC-1, MIAPaCa-2 and FL cells (data not shown). For identification of transcriptional factors that bind to the AP-1 site, supershift assays were performed with antibodies specific for c-Jun, c-Fos, CREB and ATF2. While the supershifted bands were observed only with CREB antibody in FL cells, the AP-1 DNA-protein complexes were also supershifted by the c-Jun antibody in PANC-1 cells (Figure 4b ). These results revealed that the protein components that bind to the AP-1 and CRE in PANC-1 cells are different from those in the FL cells, resulting in different inhibitory effects of DN -MEKK in FL and PANC-1 cells. In our study, Western blot analyses of pancreatic cancer tissues revealed that increased ERK activation was observed in three out of nine normal tissuematched pancreatic tumor tissues. Our data were concordant with previous reports that showed increased levels of ERK in only 20% of pancreatic cancer tissues with mutated K-ras (Yip Schneider et al., 1999) . In pancreatic cancer cell lines, similar conclusions have been obtained in recent reports (Hoshino et al., 1999; Giehl et al., 2000) . In our cases activated ERK was frequently observed in pathologically poorly differentiated tissues as compared to well and moderately differentiated types. In one case of poorly differentiated tubular adenocarcinoma and one case of anaplastic type, ERK activation was observed. These results suggested a correlation between pathological grading and ERK activation. This is the first report that directly demonstrated activation of the MEKK1 -JNK pathway in pancreatic cancers. The JNK activation in pancreatic cancers agrees with a previous report that showed that the expression of c-Jun was increased in 84% of the 33 specimens examined by immunohistochemical staining (Tessari et al., 1999) . These data suggested that activation of the MEKK1 -JNK pathway may be a crucial event in pancreatic cancer and that blocking the MEKK1 functions may be clinically useful in treatment. The MEKK1 pathway has been implicated in major cellular functions, such as cell survival, proliferation and transformation (Yujiri et al., 1998; Minamino et al., 1999; Antonyak et al., 1998; Bost et al., 1997; Clark et al., 1997; Minden et al., 1994; Smeal et al., 1991 Smeal et al., , 1992 . Recently it was also implicated in apoptosis (Leppa and Bohmann, 1999; Karin et al., 1997) .
Colony formation assays in our study indicated that DN -MEKK reduces the number but not the size of surviving colonies. These results suggest that DN -MEKK inhibits cell survival rather than cell proliferation in pancreatic cancer cells.
In vitro kinase assays and luciferase assays suggested that DN -MEKK does not suppress JNK activity in pancreatic cancer cells. EMSAs revealed that DN -MEKK inhibited their DNA-binding activities in pancreatic cancer cells and that the composition of protein complexes was different between PANC-1 cells and FL cells, suggesting that these factors lead to different effects on survival. Several recent reports have addressed the crucial role of the AP-1 compositional changes in oncogenic Ras transformation. Important roles of c-Jun and Fra-1 (Mechta et al., 1997) , c-Jun and Fra-2 (Suzuki et al., 1994) , or c-Jun, Fra-1, Fra-2 and ATF-2 (Zoumpourlis et al., 2000) are reported. These compositional changes of transcriptional factors may be a critical event in the carcinogenesis, abnormal proliferation and malignant survival of pancreatic cancers.
There is a great interest in the therapeutic application of the dominant negative mutants of members of MAP kinase cascades, which are believed to be activated by the mutant K-ras. In this study, we demonstrated that the phosphorylation of JNK is induced in all pancreatic cancer tissues and that the DN -MEKK highly suppresses the survival of pancrea- For the GAL4 fusion transactivator luciferase measurements, cells were cotransfected with either expression plasmids encoding DN -MEKK, pRL -SV40 (Promega), pFA2-cJun and pFRLuc (PathDetect Trans-Reporting System, Strategene) by electroporation. pFRLuc constructs contain five tandem repeats of Gal4 DNA consensus binding sites upstream of Photinus pyralis luciferase. pRL -SV40 was used as an internal control for transfection efficiency. Twenty-four hours after the transfection, the cells were harvested and assayed for luciferase activities by using the Dual-luciferase reporter assay system (Promega) tic cancer cells but not in non-pancreatic cancer cells. The specificity is favorable as a target for gene therapy because it may reduce cytotoxic effects on normal cells. The specific suppressive effect of DN -MEKK suggests a possible clinical use for this expression vector for gene therapy of pancreatic cancers. 
